UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018130
Receipt number R000020999
Scientific Title Efficacy of memantine treatment for the prevention and restration to cognitive dysfunction in patients receiving radiochemotherapy combined with hyperbaric oxygenation
Date of disclosure of the study information 2015/07/31
Last modified on 2020/07/03 10:24:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of memantine treatment for the prevention and restration to cognitive dysfunction in patients receiving radiochemotherapy combined with hyperbaric oxygenation

Acronym

Efficancy of memantine treatment in cognitive dysfunction of patients with malignant gliomas

Scientific Title

Efficacy of memantine treatment for the prevention and restration to cognitive dysfunction in patients receiving radiochemotherapy combined with hyperbaric oxygenation

Scientific Title:Acronym

Efficancy of memantine treatment in cognitive dysfunction of patients with malignant gliomas

Region

Japan


Condition

Condition

Patients with malignant glioma

Classification by specialty

Neurosurgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

We consider the protective effects of memantine on cognitive dysfunction in patients receiving radiotherapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Pattern separation ability
Executive function, processing speed, attention, visuo-spatial function

Key secondary outcomes

Overall survival
Progression free survival


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Patients have 5mg of memantine during radiotherapy.

Interventions/Control_2

Patients have 20mg of memantine during radiotherapy. They begin to have 5mg of memantine in the first week.Then a dose is escalating 5mg per week.

Interventions/Control_3

Patients randomly selected group have placebo tablets during radiotherapy

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The patient with malignant glioma (grade 3-4) receiving radiochemotherapy combined with hyperbaric oxygenation

Key exclusion criteria

1.Patient with hypersensitivity for memantine
2.Patients with renal dysfunction
3.Patients with having factor ascend urinary pH
4.Patients with hepatic insufficiency
5.Patients with pregnancy
6.Patients who need the continuous medication having drug interact with memantine
7.Patients who were judged by doctors as not being appropriate subjects

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Shogo
Middle name
Last name Ishiuchi

Organization

Graduate school of medicine,
University of the Ryukyus

Division name

Department of neurosurgery

Zip code

903-0125

Address

207 Nishihara-cho, Okinawa, Japan

TEL

098-895-1171

Email

ishogo@med.u-ryukyu.ac.jp


Public contact

Name of contact person

1st name Yoshiki
Middle name
Last name Oshiro

Organization

Graduate school of medicine,

Division name

Department of neurosurgery

Zip code

903-0125

Address

207 Nishihara-cho, Okinawa, Japan

TEL

098-895-1171

Homepage URL


Email

h149440@med.u-ryukyu.ac.jp


Sponsor or person

Institute

Department of neurosurgery, Graduate school of medicine, University of Ryukyus

Institute

Department

Personal name



Funding Source

Organization

self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical research center, Unversity of the Ryukyus

Address

207 Nishihara-cho, Okinawa, Japan

Tel

098-895-1509

Email

dataman.cr.ryukyu@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 07 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2015 Year 06 Month 30 Day

Date of IRB

2017 Year 12 Month 08 Day

Anticipated trial start date

2018 Year 04 Month 01 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 06 Month 30 Day

Last modified on

2020 Year 07 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020999


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name